Expression of MCCC2 in glioma cells and preliminary verification of poor prognosis.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Biomarkers in medicine Pub Date : 2025-03-04 DOI:10.1080/17520363.2025.2473131

Cheng'ao Feng, Yu Fan, Hongwei Gao, Bowen Zhang, Xiaojie Lu

{"title":"Expression of MCCC2 in glioma cells and preliminary verification of poor prognosis.","authors":"Cheng'ao Feng, Yu Fan, Hongwei Gao, Bowen Zhang, Xiaojie Lu","doi":"10.1080/17520363.2025.2473131","DOIUrl":null,"url":null,"abstract":"Aims: This study mainly explored the regulatory role and mechanism of MCCC2 in GBM.Methods: This study verified the expression in clinical samples and GBM cell lines. CCK-8 and cell cloning experiments, flow cytometry, scratch experiments and Transwell chamber experiments were used to detect the effects of MCCC2 expression on proliferation, apoptosis, migration and invasion of GBM cells.Results: A reduction in MCCC2 expression could significantly lower the protein levels of ERK, decrease p-ERK levels, and inhibit ERK phosphorylation. Ulixertinib, an ERK inhibitor, was shown to hinder the proliferation, migration, and invasion of GBM cells and counteract the regulatory impact of MCCC2 overexpression on GBM cells.Conclusions: This investigation revealed that suppressing MCCC2 expression impedes the proliferation, migration, and invasion of GBM cells and promotes GBM cell apoptosis by curtailing ERK expression and phosphorylation. This discovery implies that MCCC2 might serve as a potential biological target for anti-GBM therapy, laying the groundwork for future research in this field.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-9"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2473131","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: This study mainly explored the regulatory role and mechanism of MCCC2 in GBM.

Methods: This study verified the expression in clinical samples and GBM cell lines. CCK-8 and cell cloning experiments, flow cytometry, scratch experiments and Transwell chamber experiments were used to detect the effects of MCCC2 expression on proliferation, apoptosis, migration and invasion of GBM cells.

Results: A reduction in MCCC2 expression could significantly lower the protein levels of ERK, decrease p-ERK levels, and inhibit ERK phosphorylation. Ulixertinib, an ERK inhibitor, was shown to hinder the proliferation, migration, and invasion of GBM cells and counteract the regulatory impact of MCCC2 overexpression on GBM cells.

Conclusions: This investigation revealed that suppressing MCCC2 expression impedes the proliferation, migration, and invasion of GBM cells and promotes GBM cell apoptosis by curtailing ERK expression and phosphorylation. This discovery implies that MCCC2 might serve as a potential biological target for anti-GBM therapy, laying the groundwork for future research in this field.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.